Biocon Ltd

Mid Cap

Healthcare Sector

reflects a positive outlook for the share price

reflects a neutral outlook for the share price

reflects a negative outlook for the share price

The analysts information is for reference only and does not\n  represents an investment recommendation.

Analyst recommendation reflect the views of analysts who follow and write research reports.

Company Information is an introduction to the company’s business that details what it sell, how it was founded, what their mission is, how they manufacture or source their products, and why they serve customers.

Biocon has successfully attained 98% ownership of the equity shares in Biocon Biologics, marking a significant milestone for the company.

Biocon Achieves 98% Ownership in Biocon Biologics - 21 Jan, 2026

Biocon Limited successfully completed a Qualified Institutions Placement, raising Rs 4,150 crore to acquire Biocon Biologics and repay debts. The integration aims to strengthen its position in key therapeutic areas.

Biocon Raises Rs 4,150 Crore Through QIP - 15 Jan, 2026

Biocon's subsidiary received USFDA approval for generic Everolimus tablets. The company also initiated a QIP to raise up to ₹4,500 crore for funding growth initiatives.

Biocon Secures FDA Approval and Launches QIP - 12 Jan, 2026

Biocon plans to integrate Biocon Biologics as a subsidiary, launching three new oncology biosimilars. However, the company faces a significant decline in US sales.

Biocon Expands Oncology Portfolio Amid Sales Decline - 06 Jan, 2026

A 26-year-old Biocon employee, S Anantha Kumar, tragically died by suicide after jumping from the fifth floor of the office building in Bengaluru. Biocon expressed deep condolences.

Tragic Death of Biocon Employee in Bengaluru - 31 Dec, 2025

Biocon has entered an out-licensing agreement with Ajanta Pharma to market Semaglutide, enhancing its presence in diabetes care across multiple regions.

Biocon Partners with Ajanta Pharma for Semaglutide - 24 Dec, 2025

Biocon Biologics has secured full global rights for biosimilar Hulio, while a partnership with Ajanta Pharma expands its GLP-1 portfolio. Kiran Mazumdar-Shaw emphasizes the value of the Biocon-Biologics deal. Biocon's stock has shown consistent gains, rising 0.1% on December 23.

Biocon Expands Global Reach and Gains Market Value - 23 Dec, 2025

Price to Earnings Ratio or Price to Earnings Multiple is the ratio of the share price of a stock to its earnings per share (EPS). It provides an indication of whether a stock at its current market price is expensive or cheap.

The price/earnings-to-growth ratio, or the PEG ratio, is a metric that helps investors value a stock by taking into account a company's market price, its earnings, and its future growth prospects.

Enterprise value (EV) is the total value of a company, defined in terms of its financing. It includes both the current share price (market capitalization) and the cost to pay off debt (net debt, or debt minus cash).

Alpha measures the amount that the investment has returned in comparison to the market index or other broad benchmark that it is compared against.

Beta measures a stock's volatility, the degree to which its price fluctuates in relation to the overall stock market. In other words, it gives a sense of the stock's risk compared to that of the greater market.

Dividend yield measures the quantum of earnings by way of total dividends that investors make by investing in that company.

The debt-to-total-assets ratio shows how much of a business is owned by creditors (people it has borrowed money from) compared with how much of the company's assets are owned by shareholders.

Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations.

This widget shows the information about the stock's peers in consideration along with the different data for those peers so that the user can compare the stock with the other similar stock and invest accordingly.

Promoter holding is the amount of share of the company that is owned by the promoters. The promoters are the company's founders, who hold a majority stake in the company's capital.

A foreign institutional investor (FII) is an investor or investment fund investing in a country outside of the one in which it is registered or headquartered.

A mutual fund is a pool of money managed by a professional Fund Manager. It is a trust that collects money from a number of investors who share a common investment objective and invests the same in equities, bonds, money market instruments, and other securities.

Retail investors execute their trades through traditional or online brokerage firms or other types of investment accounts. Retail investors purchase securities for their own personal accounts and often trade in dramatically smaller amounts as compared to institutional investors.

This widget shows the bifurcation of stocks based on the percentage of stake with the different types of shareholders.

This widget will help value the stock based on the Price to Earning ratio of the stock and compare the valuation with the industry value and other similar stocks. It even shows the timeline of the valuation of the stock and its highest and lowest valuation over time.
A Time Series data is provided which compares the historical stock PE with Industry PE over the period of 5 years.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

Netprofit is up for the last 2 quarters, 31.4 Cr → 84.5 Cr (in ₹), with an average increase of 62.8% per quarter

This section gives you an insight into how the profit for the company has been for the last few quarters.

Profit Spike

In the last 3 months, BIOCON stock has moved up by 0.2%

This section gives you an insight into the price movement of the stock for the last few quarters.

Price Rise

Retail Investor have increased holdings from 16.69% to 25.42% in Dec 2025 quarter

This section gives you an insight into how the Retail Investors Holding has changed for the stock over last few quarters.

Retail Holding Up

Revenue is up for the last 2 quarters, 4.02K Cr → 4.38K Cr (in ₹), with an average increase of 8.4% per quarter

This section gives you an insight into how the revenue of the company has moved for the last few quarters.

Revenue Rich

In the last 1 year, Take Solutions Ltd has given 169.1% return, outperforming this stock by 175.2%

This section gives you an insight into how the peers have performed as compared to this company in the last 1 year.

Against Peers

In the last 3 years, Vimta Labs Ltd has given 149.6% return, outperforming this stock by 101.9%

This section gives you an insight into how the peers have performed as compared to this company in the last 3 years.

Promoters have decreased holdings from 54.45% to 48.27% in Dec 2025 quarter

This section gives you an insight into how the Promoter Holding has changed for the stock over the last few quarters.

Promoter Holding Down

Mutual Funds have decreased holdings from 14.13% to 12.17% in Dec 2025 quarter

This section gives you an insight into how the Mutual Funds Holding has changed for the stock over last few quarters.

MF Holding Down

Foreign Institutions have decreased holdings from 6.61% to 6.56% in Dec 2025 quarter

This section gives you an insight into how the FII Holding has changed for the stock over last few quarters.

FII Holding Down

Nifty Midcap 100

Nifty Healthcare

Nifty Midcap 150

BSE Healthcare

S&P BSE 250 LargeMidCap

BSE 200

S&P BSE 150 MidCap

Nifty MidSmallcap 400

Nifty 200

BSE Mid-Cap

Nifty LargeMidcap 250

S&P BSE 400 MidSmallCap

NIFTY PHARMA

BSE 500

Nifty 500

SBI Contra Fund Direct Growth

SBI Midcap Fund Direct Growth

Kotak Large & Midcap Direct Growth

SBI Large & Midcap Fund Direct Growth

SBI Balanced Advantage Fund Direct Growth

Biocon Ltd’s net profit jumped 628.13% since last year same period to ₹84.50Cr in the Q2 2025-2026. On a quarterly growth basis, Biocon Ltd has generated 169.11% jump in its net profits since last 3-months.

Name	Value	Action
MACD level (12,26)	0.29	Bearish
CCI (20)	-31.48	Neutral
RSI (14)	50.55	Neutral
Momentum (10)	-0.1	Bearish
ADI (14)	22.72	Neutral
Ultimate Oscillator (7,14,28)	55.58	Neutral

Name	Value	Action
SMA (20)	364.95	Bearish
EMA (20)	365.05	Bearish
VWMA (20)	365.19	Bearish
SMA (50)	364.5	Bullish
EMA (50)	364.55	Bullish
SMA (200)	364.57	Bullish
EMA (200)	364.26	Bullish
KAMA (200)	364.57	Bullish
DEMA (200)	363.96	Bullish

Biocon Ltd (BIOCON)

Summary

Overall

Oscillators

Moving Averages